2 monster growth stocks in the making

Royston Wild looks at two stocks with terrific earnings potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

PureCircle (LSE: PURE) found itself backpeddling in Tuesday trading following a less-than-enthusiastic reception to full-year trading numbers.

The stock was last 4% lower on the day, retreating further from September’s 28-month tops, above 480p per share. However, this is reflective of mere profit taking rather than signs for concern as PureCircle’s market value has almost doubled since the start of the 2017.

The stevia sweetener producer advised that revenues during the 12 months to June 2017 fell 14% year-on-year to £118.9m, and this pushed operating profit 47% lower to £17.6m.

PureCircle was whacked by the US Customs & Border Protection, placing the firm on its Withhold Release Order (WRO) list. That saw its products banned for import last year while allegations that they were produced by forced labour in China were being investigated.

The ban was lifted in January, but the firm advised that “the impact of this WRO on our business was significant and continues to be felt today,”  and that it will take time to build up US momentum again in a market generated a third of its total sales in 2016.

On the right track again

While the first half result was disappointing (if not surprising), there was still  plenty to take away from PureCircle’s release. Sales outside the US increased by a healthy 8% during fiscal 2017, illustrating the strength of global demand for stevia products.

And the Malaysian company continued to invest heavily last year to underpin future sales growth. It invested $42m it its stevia refinery in Malaysia, and the huge sums it has dedicated to product R&D saw 124 new products hit the shelves last year.

With sales of the sweetener booming across the globe, and the troubles it experienced in the States now behind it, I believe PureCircle can look forward to exceptional earnings growth in the years ahead. And City analysts have predicted a 130% bottom-line rise in the current fiscal year alone.

A forward P/E ratio of 62.9 times may look unappealing on paper, although a sub-1 PEG reading of 0.5 suggests the business is actually attractively priced relative to its growth prospects. I reckon PureCircle is a very attractive investment destination.

Upping the pace

I’m also convinced that demand for The Gym Group’s (LSE: GYM) cheap fitness passes should continue to boom as growing restraints on Britons’ spending power worsens, and the keep fit craze drives ever-more people onto the treadmill.

The Guildford-based business saw revenues shoot 19% higher during January-June to £42.8m, and the low-cost operator continues to aggressively expand to bolster sales growth. Last week, the group snapped up 18 gyms from Lifestyle Fitness for £20.5m, and plans to open 20 new sites under its organic rollout programme this year alone.

Against this backcloth, City brokers predict earnings expansion of 34% and 19% for 2017 and 2018, respectively, resulting in a prospective P/E rating of 28.4 times and a corresponding PEG multiple of 0.8. I reckon The Gym  Group is also worthy of serious consideration at the present time.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 for a Stocks and Shares ISA? Here’s how to try and turn it into a monthly passive income of £493

Hundreds of pounds in passive income a month from a £20k Stocks and Shares ISA? Here's how that might work…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£5,000 put into Nvidia stock last Christmas is already worth this much!

A year ago, Nvidia stock was already riding high -- but it's gained value since. Our writer explores why and…

Read more »

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »